These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29186300)

  • 1. Unsweetening the Heart: Possible Pleiotropic Effects of SGLT2 Inhibitors on Cardio and Cerebrovascular Alterations in Resistant Hypertensive Subjects.
    Pioli MR; Ritter AMV; Modolo R
    Am J Hypertens; 2018 Feb; 31(3):274-280. PubMed ID: 29186300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose Cotransporter 2 Inhibitors and Ischemic Stroke.
    Milonas D; Tziomalos K
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):134-138. PubMed ID: 29412119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAIT-survey-Prevalence of albuminuria in patients with diabetes and hypertension in Turkey.
    Fici F; Bakir EA; Beyaz S; Makel W; Robles NR
    Prim Care Diabetes; 2018 Dec; 12(6):558-564. PubMed ID: 30327190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension.
    Sanidas EA; Papadopoulos DP; Hatziagelaki E; Grassos C; Velliou M; Barbetseas J
    Am J Hypertens; 2020 Mar; 33(3):207-213. PubMed ID: 31541572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
    Giugliano D; Longo M; Scappaticcio L; Caruso P; Esposito K
    Cardiovasc Diabetol; 2021 Jan; 20(1):17. PubMed ID: 33430860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
    Bertero E; Prates Roma L; Ameri P; Maack C
    Cardiovasc Res; 2018 Jan; 114(1):12-18. PubMed ID: 29016751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Greene SJ; Butler J
    Circulation; 2019 Jan; 139(2):152-154. PubMed ID: 30615507
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis.
    Kang Y; Zhan F; He M; Liu Z; Song X
    Vascul Pharmacol; 2020; 133-134():106779. PubMed ID: 32814163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat.
    Younis F; Leor J; Abassi Z; Landa N; Rath L; Hollander K; Naftali-Shani N; Rosenthal T
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):358-371. PubMed ID: 29627992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?
    Santos-Ferreira D; Gonçalves-Teixeira P; Fontes-Carvalho R
    Cardiology; 2020; 145(5):311-320. PubMed ID: 31865310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs.
    Imprialos KP; Stavropoulos K; Stavropoulos N; Patoulias D; Petidis K; Grassos C; Dimitriadis K; Tsioufis C
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):104-113. PubMed ID: 29412121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class effect for SGLT-2 inhibitors: a tale of 9 drugs.
    Giugliano D; Esposito K
    Cardiovasc Diabetol; 2019 Jul; 18(1):94. PubMed ID: 31337395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
    Papademetriou V; Geladari E
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.